Use of erlotinib in patients selected using clinical criteria in the 2nd and 3rd line treatment of non-small cell lung cancer (NSCLC)F. Stavridi,S. Eestila,S. Merchant,P. Cane,J. SpicerLung Cancer(2009)引用 0|浏览3暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要